OBJECTIVE: To report and synthesize patterns of disease-modifying antirheumatic drug (DMARD) use reported in observational studies of patients with established and early rheumatoid arthritis (RA) after publication of the American College of Rheumatology guidelines promoting universal DMARD use. METHODS: We searched PubMed for full-length articles in English published between January 1, 2002 and October 1, 2012 that examined DMARD use. The data abstracted from articles included the patient characteristics, country of study, time period studied, patient source, and treating physician type. Study quality was assessed using a modified Newcastle-Ottawa Quality Assessment Scale. RESULTS: We reviewed 1,287 abstracts; 98 full-length articles were selected for additional review and 27 studies describing 28 cohorts of patients were included. Twelve studies described data from cohorts of patients with established RA, and DMARD use in this group of studies ranged from 73-100%. Five studies described data from patients sourced through administrative data and demonstrated consistently lower DMARD use, ranging from 30-63%. Three studies conducted population-based surveys to define cases of RA where DMARD use ranged from 47-73%. Eight studies investigated patients with early RA. DMARD use among patients followed by rheumatologists ranged from 77-98%, whereas DMARD use reported for patients seen by a mix of physicians was significantly lower (39-63%). CONCLUSION: DMARD use in studies from RA cohorts or registries (in which patients were followed by rheumatologists) ranged from 73-100%, compared with 30-73% in studies from administrative data or population-based surveys (in which patients were not necessarily receiving rheumatology subspecialty care).
OBJECTIVE: To report and synthesize patterns of disease-modifying antirheumatic drug (DMARD) use reported in observational studies of patients with established and early rheumatoid arthritis (RA) after publication of the American College of Rheumatology guidelines promoting universal DMARD use. METHODS: We searched PubMed for full-length articles in English published between January 1, 2002 and October 1, 2012 that examined DMARD use. The data abstracted from articles included the patient characteristics, country of study, time period studied, patient source, and treating physician type. Study quality was assessed using a modified Newcastle-Ottawa Quality Assessment Scale. RESULTS: We reviewed 1,287 abstracts; 98 full-length articles were selected for additional review and 27 studies describing 28 cohorts of patients were included. Twelve studies described data from cohorts of patients with established RA, and DMARD use in this group of studies ranged from 73-100%. Five studies described data from patients sourced through administrative data and demonstrated consistently lower DMARD use, ranging from 30-63%. Three studies conducted population-based surveys to define cases of RA where DMARD use ranged from 47-73%. Eight studies investigated patients with early RA. DMARD use among patients followed by rheumatologists ranged from 77-98%, whereas DMARD use reported for patients seen by a mix of physicians was significantly lower (39-63%). CONCLUSION: DMARD use in studies from RA cohorts or registries (in which patients were followed by rheumatologists) ranged from 73-100%, compared with 30-73% in studies from administrative data or population-based surveys (in which patients were not necessarily receiving rheumatology subspecialty care).
Authors: J N Katz; J Barrett; M H Liang; A M Bacon; H Kaplan; R I Kieval; S M Lindsey; W N Roberts; D M Sheff; R T Spencer; A L Weaver; J A Baron Journal: Arthritis Rheum Date: 1997-09
Authors: Catherine H MacLean; Kenneth G Saag; Daniel H Solomon; Sally C Morton; Sarah Sampsel; John H Klippel Journal: Arthritis Rheum Date: 2004-04-15
Authors: Esi Morgan DeWitt; Li Lin; Henry A Glick; Kevin J Anstrom; Kevin A Schulman; Shelby D Reed Journal: Clin Ther Date: 2009-08 Impact factor: 3.393
Authors: Maria D Mjaavatten; Helga Radner; Kazuki Yoshida; Nancy A Shadick; Michelle L Frits; Christine K Iannaccone; Tore K Kvien; Michael E Weinblatt; Daniel H Solomon Journal: Semin Arthritis Rheum Date: 2014-08-27 Impact factor: 5.532
Authors: Tzu-Chieh Lin; Kazuki Yoshida; Sara K Tedeschi; Mirhelen Mendes de Abreu; Nikroo Hashemi; Daniel H Solomon Journal: Arthritis Care Res (Hoboken) Date: 2018-04-12 Impact factor: 4.794
Authors: Maria D Mjaavatten; Helga Radner; Kazuki Yoshida; Nancy A Shadick; Michelle L Frits; Christine K Iannaccone; Tore K Kvien; Michael E Weinblatt; Daniel H Solomon Journal: J Rheumatol Date: 2014-10-15 Impact factor: 4.666
Authors: Beth I Wallace; Paul Lin; Neil Kamdar; Mohamed Noureldin; Rodney Hayward; David A Fox; Jeffrey R Curtis; Kenneth G Saag; Akbar K Waljee Journal: Semin Arthritis Rheum Date: 2019-09-07 Impact factor: 5.532
Authors: Cristiano S Moura; Michal Abrahamowicz; Marie-Eve Beauchamp; Diane Lacaille; Yishu Wang; Gilles Boire; Paul R Fortin; Louis Bessette; Claire Bombardier; Jessica Widdifield; John G Hanly; Debbie Feldman; Walter Maksymowych; Christine Peschken; Cheryl Barnabe; Steve Edworthy; Sasha Bernatsky Journal: Arthritis Res Ther Date: 2015-08-03 Impact factor: 5.156